Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Amesite Inc. (NASDAQ: AMST) to Launch Pilot Program, Provide AI-Based Solution to EWIE Group of Companies

Amesite (NASDAQ: AMST), an artificial intelligence (“AI”) software company providing advanced AI-powered online learning ecosystems for business and higher education, today announced that it is launching a pilot program with the EWIE Group of Companies (“EGC”) to develop and implement an eLearning and eTraining platform for its employees across the globe. According to the update, the platform will provide program, process and technology learning and training while also allowing managers to assess program and process understanding of their team members. The AI-based Amesite solution will integrate data from multiple platforms, enabling EGC to harness the full potential of its human resources to create value for its customers and shareholders. “This contract is another big win for Amesite. We are particularly proud to be partnering with EGC, a global leader in manufacturing and supply chain management services. This opportunity is more evidence that our online content and delivery systems are a best-in-class solution for multiple industries,” said Dr. Ann Marie Sastry, founder and CEO of Amesite. “Our easy-to-use platform continues to gain traction in the marketplace because of the capabilities of our AI technology. I am excited to move forward with the implementation of our platform for another industry leading company.”

To view the full press release, visit https://ibn.fm/XB5De

About Amesite Inc.

Amesite is an ed-tech, software-as-a-service (“SaaS”) company with the most advanced artificial intelligence-driven online learning platform in the industry, providing both content creation and a best-in-class infrastructure for the multibillion online learning markets in business and education. For more information, visit www.Amesite.com.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at https://ibn.fm/AMST

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Amesite Inc. AMST | Leave a comment

MissionIRNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Announces Planned Release of Q1 2021 Financial Results, Conference Call

Trxade Group (NASDAQ: MEDS),a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States, has announced that it will its first-quarter 2021 financial results after market close on April 26, 2021. As part of that release, the company has scheduled a conference call on Monday, April 26, 2021, at 5 p.m. ET. That call will include discussion of the financial report and will also include time for a Q&A session. Interested participants can dial in from the United States (1-877-425-9470) using the conference ID 13718446. Those dialing in are encouraged to call in at least 10 minutes before the call is scheduled to begin. Participants can also view the event via webcast. In addition, a playback of the conference call will be available through May 26, 2021, by calling 1-844-512-2921 within the United States or 1-412-317-6671 internationally and entering the pin number 13718446.

To register for the webcast, visit https://ibn.fm/3nB89

To view the full press release, visit https://ibn.fm/6MMyh

About Trxade Group Inc.

Trxade Group is a health-services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States. The company operates the TRxADE drug-procurement marketplace serving a total of 11,800-plus members nationwide and fostering price transparency as well as the Bonum Health brand, offering patient centric telehealth services. For more information about the company, please visit www.Trxade.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Trxade Group Inc. (MEDS) | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Advancement of IND-Enabling Studies of Psychedelic Molecules for IND Applications

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has plans to advance the preclinical work for two of its deuterated tryptamine development candidates: its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation of CYB004. In the announcement, the company noted that the planned studies are part of the required U.S. Food and Drug Administration (“FDA”) enabling trials for investigational new drug applications (“INDs”). The results of the studies will be included in the submissions to the FDA and other regulatory bodies, including Health Canada and European Medical Association (“EMA”). The proprietary Cybin molecules are designed to have a faster onset and a shorter duration of action while still delivering the clinical benefits of psilocybin and other psychedelic compounds in development. They are being developed using an FDA-approved inhalation platform and proprietary ODT technology; if successful, the company intends to use the psychedelic molecules to improve therapeutic outcomes for psychiatric conditions. If successful, the candidates would advance into Phase 1 human clinical trials for specified psychiatric conditions. “Starting the IND-enabling trials for CYB003 and CYB004 is an exciting and important step forward for Cybin as we progress the study of these molecules,” said Cybin CEO Doug Drysdale in the press release. “Our scientific team is eager to produce a robust submission to the FDA that will advance our path forward to clinical trials. Once the studies have been completed, we plan to file IND applications, targeting treatment-resistant psychiatric disorders and certain forms of addiction, in 2021.”

To view the full press release, visit https://ibn.fm/1Nqcr

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Knightscope Inc. Announces New Service for Clients without SOC

Knightscope, an advanced security technology company that builds fully autonomous security robots that deter, detect and report, has announced a new revenue-generating monitoring and response capability. In the announcement, company noted that most of its current clients have a fully staffed Security Operations Center (“SOC”) that includes a team that utilizes Knightscope technology 24/7 to assist in securing designated locations. However, the company does have a number of prospective clients that do not have the resources for a fully staffed SOC. With that in mind, the company now offers an additional service for its Autonomous Security Robots (“ASR”), which include backup by former military and law enforcement experienced professionals who provide active monitoring of alerts, audio deterrence through proactive use of Knightscope’s broadcast and intercom features, as well as escalation to 911 when necessary. “Since law enforcement will know that the alerts have been vetted and that there is an active situation, they are better prepared to respond and are less likely to fall victim to complacency,” the company explained in the press release, noting that more than 90% of traditional alarms are false. “We are excited to be able to continue to improve our technology offering for our clients as we grow.”

To view the full press release, visit https://ibn.fm/nEkOY

About Knightscope Inc.

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knight are available in the company’s newsroom at https://ibn.fm/Knight

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Knightscope, Inc. | Leave a comment

MissionIRNewsBreaks – TAATLifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) CEO Scheduled to Present at Global Chinese Financial Forum Virtual Event

TAAT Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) CEO Settie Coscarella is slated to present at the upcoming Investing in Innovation Global Chinese Financial Forum (“GCFF”). The online event is scheduled for Thursday, April 15; Coscarella’s 20-minute presentation will begin at 1:25 pm EDT and will include an explanation of TAAT’s unique position in the $814 billion global tobacco industry as well as company’s impressive progress since its launch last year. Coscarella will talk about the company’s U.S. product launch in Ohio and online as the company has focused on making the product available to the majority of smokers aged 21 and above in the United States. The GCFF series of events is produced by NAI Interactive Ltd. (“NAI”), a market intelligence and investor relations service provider founded in 1998 with offices in Vancouver and Shanghai; the events are designed to connect North American public companies with Chinese investors. Recent GCFF events include Diversified Investing Strategies, Base Metals & Energy Metals Day, and Precious Metals Day. “Now that we are establishing a presence in our initial market, we have a great story to share with a global audience of investors who may not yet be familiar with TAAT and its unique value proposition for smokers aged 21+,” said TAAT CEO Setti Coscarella in the press release. “The concept of a smokable product with no tobacco or nicotine is very novel, and it has attracted considerable interest from investors in China, whose population of tobacco smokers is approximately eight times the size of Canada’s total population. It has been a pleasure to work with NAI to create a presentation for the GCFF Investing in Innovationevent on Thursday, and I am looking forward to sharing our message with an eager and engaged audience of global investors as we continue to gain momentum with the launch of TAAT in the United States.”

To register for the event, visit https://ibn.fm/E2PC6

To view the full press release, visit https://ibn.fm/yxAcT

About TAAT Lifestyle & Wellness Ltd.

TAAT Lifestyle and Wellness has developed TAAT,  which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.  

NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in TAAT Lifestyle & Wellness Ltd. TOBAF | Leave a comment

MissionIRNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Collaborates to End 20-Year Drought with New Initiative

Energy Fuels (NYSE American: UUUU) (TSX: EFR) has partnered with Neo Performance Materials (TSX: NEO) in an initiative that will see feedstock from the United States being used to manufacture separated rare earth (“RE”) materials outside China for the first time in over 20 years. “A leading U.S.-based uranium mining company, Energy Fuels, has been working with Neo for almost a year in a technical collaboration focused on establishing a monazite processing and RE carbonate production capacity at Energy Fuels’ White Mesa Mill plant in Utah,” reads an article detailing the partnership. “That successful collaboration has led to the current initiative, which marks the first time in more than 20 years that monazite ore from the United States will be used as a feedstock to manufacture separated rare earth materials outside of China. The agreement calls for Energy Fuels to process natural monazite sands, which it obtains from the Chemours Company (NYSE: CC), into an RE carbonate beginning next year and ship a portion of that production to Neo’s rare earth separation facility in Estonia.”

To view the full article, visit https://ibn.fm/WSOdR

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest N.I. 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Energy Fuels Inc. UUUU | Leave a comment

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Files First Order for Rapid COVID Test Kits Amid European Regulatory Approval

  • Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner
  • XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards
  • The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April
  • XPhyto has just completed a rebranding effort that includes the launch of a new website
  • The company expects to begin launching other bacteria and virus diagnostic products later this year

With confidence in the world’s mounting recovery from the COVID-19 pandemic growing this year, bioscience industry holding company XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is stepping up its efforts to produce and ultimately commercialize next-generation diagnostic products and new active pharmaceutical ingredients, particularly in regard to the pandemic response.

XPhyto has placed its first order for the company’s Covid-ID Lab product from its exclusive diagnostic development partner, Germany’s 3a-diagnostics GmbH, as announced in a Feb. 24 news release (https://ibn.fm/uBX94). The Covid-ID Lab is a rapid, point-of-care RT-PCR test system for COVID that the company expects to be useful for industry partners and licensees, as well as their respective government regulators, in safeguarding against the spread of the highly infectious and potentially fatal virus.

The first product order from 3a was for 9,600 tests, which are packaged in 200 kits of 48 tests each, according to the company. Delivery is expected this month and XPhyto anticipates they will then undergo evaluation by the company’s partners and the appropriate government agencies for expected commencement of sales in Q2 2021.

“We are pleased to report that all steps towards the launch of Covid-ID Lab remain on track within an ambitious timeline,” XPhyto CEO and Director Hugh Rogers stated in the news release. “Our experienced market launch team is working quickly to bring the product to market, as well as to establish licensing and distribution partnerships. We are confident that Covid-ID Lab, as a 25-minute PCR test with minimal technical and personnel requirements, will be a stand-out product in the COVID-19 test market.”

In March, XPhyto received two critical regulatory approvals in Europe to open the door for sales of its rapid, point-of-care COVID testing solution. On March 10, the company announced approval for commercial production under internationally agreed-on ISO 13485 quality standards (https://ibn.fm/qZCXm). On March 18, the company further announced Covid-ID Lab’s approval for in vitro diagnostic device (CE-IVD) use (https://ibn.fm/PqsZI).

On March 4, XPhyto announced completion of a corporate rebranding initiative that includes the launch of a new website.

“The company is excited to introduce a fresh look at such a pivotal point in our business growth,” Rogers added (https://ibn.fm/A4hzB).

XPhyto is on track to launch sales and distribution in Europe in April, and the company is also in talks with potential distribution and wholesale partners in the Middle East.

XPhyto intends to continue its rapid, point-of-care product development to target other pandemic-potential illnesses, such as H1N1 (swine flu) and H5N1 (avian flu), as well as a variety of other bacterial and viral infectious diseases. New products under an expanding portfolio could be launched before the end of the year.

XPhyto’s research and development operations are located in North America and Europe, but the company’s focus is the European market during these initial stages of product placement.

For more information on XPhyto Therapeutics, visit the company’s newly designed website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in XPhyto Therapeutics Corp. XPHYF | Leave a comment

Brain Scientific Inc. (BRSF) Changing the Landscape by Tackling Neurology Deserts

  • Distribution of neurologists across the U.S. is uneven with 20 states experiencing neurology deserts
  • Brain Scientific has developed tools that help providers in neurology deserts provide access to neurological care
  • With explosion of telemedicine services and increased integration of advanced practice providers, neurologists’ shortage may improve

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is directly tackling the shortage of neurologists in the United States with cutting-edge technologies. By creating cost-efficient, disposable and portable EEGs, BRSF makes neurology care more accessible without putting excess strain on the already overextended neurologist labor pool.

Between 2001 and 2016, the American Academy of Neurology (“AAN”) reported that out-of-pocket costs shot up substantially for privately insured patients. In addition, the distribution of neurologists across the U.S. is uneven, with patients in rural areas less likely to receive care (https://ibn.fm/9sUYR). There are 20 states, according to the 2017 Alzheimer’s Association International Conference, classified as neurology deserts (https://ibn.fm/cGx2k). This term designates an area that has projected a chronic shortage of neurologists alongside a rise in dementia cases.

“In many places, people do not have easy access to specialists, for a variety of reasons. But you may not need a neurologist in every case,” said Beth Kallmyer, MSW, vice president of Constituent Services at the Alzheimer’s Association. “With the right training and tools, primary care physicians can effectively diagnose and treat Alzheimer’s disease. The Alzheimer’s Association is working to arm primary care physicians with the tools they need to manage an increased caseload, as well as care planning guidance.”

Brain Scientific has developed tools that provide primary care physicians in neurology deserts the ability to serve their patients and create specialized treatment plans that provide access to neurologists. Portable, clinical-grade, easy-to-use diagnostic devices are now in place to allow to run EEG tests withing a few minutes. The company is actively working on a secure, cloud-based and highly scalable infrastructure to transmit patient data between neurologists and patients as well as creating artificial intelligence assisted diagnostic analysis.

Currently, across the United States, there is significant disparity between who has access to neurology care and who does not. A MedPate Today article reported that the lowest density had a mean of 9.7 neurologists for every 100,000 Medicare beneficiaries while the highest had 43.1 neurologists for every 100,000 (https://ibn.fm/dGCud). While the number of conditions remained similar, the access to care did not. With the explosion of telemedicine services and an increased integration of advanced practice providers, neurologists’ shortage may just improve.

Through portable EEGs, teleneurology, on-demand data exchange and AI predictive biomarkers, Brain Scientific will create resources to narrow this wide gap. The company’s commercialized products were designed to disrupt the slow, expensive and cumbersome EEG market with easy-to-use, economical and disposable solutions. These devices are so easy to use that any medical professional can use them within minutes in any setting to run routine EEG studies.

Brain Scientific can potentially change the United States’ landscape and eliminate neurology deserts once and for all. It’s time everyone had access to the life-saving research available.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Brain Scientific Inc. BRSF | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (“NSCLC”). According to the update, collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. The data were presented at the 2021 American Association of Cancer Research (“AACR”) annual meeting. “We are pleased to have these positive data that provide further support for the therapeutic potential of REQORSA in combination with immunotherapies and targeted therapies in NSCLC presented before an audience of the world’s leading cancer researchers. These data are particularly encouraging as we look to initiate our upcoming combination Acclaim-1 and Acclaim-2 clinical trials of REQORSA in NSCLC,” said Rodney Varner, president and chief executive officer of Genprex. “We know that many patients inevitably develop resistance to immune checkpoint blockade therapy or EGFR-TKI therapy. These data show that REQORSA in combination with immunotherapies and targeted therapies may provide enhanced efficacy in NSCLC that has become resistant to these regimens, offering hope to a large patient population who currently has limited treatment options.”

To view the full press release, visit https://ibn.fm/uRXhj

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Has Keen Interest in President’s Supply Chain Review

  • Biden calls for 100-day review of strategic supply chains
  • Already leading uranium/vanadium producer, UUUU has made significant strides in REE space in 2021
  • Energy Fuels on schedule to produce intermediate rare earth product in 2021

In the midst of President Joe Biden’s 100-day review of U.S. strategic supply chains (https://ibn.fm/jc5jW), companies around the country, including Energy Fuels (NYSE American: UUUU) (TSX: EFR), are watching closely for the results. Last year, Energy Fuels, the country’s largest producer of uranium and the leading conventional producer of vanadium, announced plans to enter the rare earth elements (“REE”) space. Just under a year later, the company is about to begin commercial production of an intermediate rare earth product at its facility in Utah. This product contains excellent distributions of the rare earths needed for electric vehicles (“EVs”), renewable energy systems, batteries, technology, and military and defense applications.

The supply chain review is intended to boost manufacturing jobs by strengthening U.S. supply chains for advanced batteries, pharmaceuticals, critical minerals and semiconductors; the review will also examine the nation’s reliance on imports of these goods — a potential national security and economic risk that the Biden administration hopes to address.

“These are the kinds of common sense solutions that all Americans can get behind,” Biden said, discussing the review. “It’s about resilience, identifying possible points of vulnerabilities in our supply chains and making sure we have the backup alternatives or workarounds in place.”

The review appeared to be distinctly bipartisan; an AP article reported that Biden met with Republican and Democratic lawmakers at the Oval Office before signing the order. “This is a critical area where Republicans and Democrats agreed — it was one of the best meetings I think we’ve had so far and we’ve only been here about five weeks,” Biden said. “It was like the old days. People were actually on the same page.”

Energy Fuels has a keen interest in the outcome of the analysis. Last year, the company announced its interest in entering the REE market as a complement to its core uranium and recycling businesses. Since that announcement, the company has emerged as a major player in the commercial rare earth business. Its initial goal was to enter the commercial REE business in H1 2021, working to supply up to 50% of U.S. rare earth demand contained in a mixed REE carbonate over the next few years.

The company is expected to soon begin processing its first monazite ore at its White Mesa Mill in Blanding, Utah, and producing a marketable mixed rare earth element carbonate. If successful Energy Fuels will be producing a rare earth product at a stage more advanced than any other U.S. company. This work represents a crucial step toward re-establishing a fully integrated U.S. rare earth element supply chain.

In addition, the company has plans to install REE separation and additional downstream capabilities over the next few years. These plans can be implemented within the company’s existing infrastructure (https://ibn.fm/gSXQP). With its expansion into the growing REE market, strong balance sheet, diverse business opportunities, and all debt paid off last year, the company is leveraging a robust business model that allows it to be well positioned to capitalize on the increasing momentum for the REE space.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Energy Fuels Inc. UUUU | Leave a comment